Proprietary information on the chemical composition of our SRED formulations (SP3, SP4, and SP5) is available to prospective investors under a confidentiality agreement. Pre-clinical validation and proof-of-concept studies include the following references:
Luu, Jennings et al. “Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition.” Proceedings of the National Academy of Sciences of the United States of America vol. 120,19 (2023): e2221045120. doi:10.1073/pnas.2221045120
Featured in:
1. “Eye-Opening Drug Discovery May Help Treat Age-Related Macular Degeneration.” Neuroscience News, 8 May 2023.
2. “UCI Researchers Discover New Drugs with Potential for Treating World’s Leading Causes of Blindness.” National Eye Institute: Research News, 8 May 2023.
3. “Team Discovers New Drugs with Potential for Treating World’s Leading Causes of Blindness in AMD, Other Diseases.” Medical Xpress, 8 May 2023.
4. “New Drugs with Potential to Treat Leading Causes of Blindness Discovered.” Technology Networks, 9 May 2023.
5. “Team Discovers New Drugs for AMD and Other Diseases.” Ophthalmology Breaking News, 9 May 2023.
6. Henderson, Emily. “New Small-Molecule Drugs Show Potential Clinical Utility in Treating World’s Leading Causes of Blindness.” News-Medical, 9 May 2023.
7. Crago, Sydney M. “Stress Resilience-Enhancing Drugs May Provide New Therapeutics to Treat AMD, DR, and RP.” Modern Retina, 11 May 2023.
8. Bhattacharya, Sanjana. "New class of therapeutics may treat retinal diseases." Glance by Eyes On Eyecare, 24 May 2023.
Luu, Jennings et al. “Epigenetic hallmarks of age-related macular degeneration are recapitulated in a photosensitive mouse model.” Human molecular genetics vol. 29,15 (2020): 2611-2624. doi:10.1093/hmg/ddaa158
Luu, Jennings, and Krzysztof Palczewski. “Human aging and disease: Lessons from age-related macular degeneration.” Proceedings of the National Academy of Sciences of the United States of America vol. 115,12 (2018): 2866-2872. doi:10.1073/pnas.1721033115
Orban, Tivadar et al. “A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration.” The Journal of pharmacology and experimental therapeutics vol. 364,2 (2018): 207-220. doi:10.1124/jpet.117.245167
Chen, Yu et al. “Synergistically acting agonists and antagonists of G protein-coupled receptors prevent photoreceptor cell degeneration.” Science signaling vol. 9,438 ra74. 26 Jul. 2016, doi:10.1126/scisignal.aag0245
We are a privately-held company; investment inquiries may be submitted in the form linked above or via email to investor@hyperioneye.com.
We are classified as a for-profit, C-corporation.
Hyperion Therapeutics, Inc. was incorporated in the state of Delaware, USA in 2022.
We currently have multiple office locations across the United States of America in:
1) Newport Beach, California
2) Irvine, California
3) Cleveland, Ohio
Our company namesake, the son of Gaia and Uranus, father of Selene and Helios, Hyperion is the Greek Titan God of Light!